痴呆
阶段（地层学）
食品药品监督管理局
认知障碍
疾病
医学
阿尔茨海默病
载脂蛋白E
老年学
内科学
药理学
生物
古生物学
作者
Hai V. Nguyen,Shweta Mital,David S. Knopman,G. Caleb Alexander
出处
期刊：Neurology
[Lippincott Williams & Wilkins]
日期：2024-03-14
卷期号：102 (7)
被引量：18
标识
DOI：10.1212/wnl.0000000000209218
摘要
Little is known regarding the cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). This study aims to quantify the cost-effectiveness of lecanemab and how it varies based on the accuracy of AD testing and individuals'
科研通智能强力驱动
Strongly Powered by AbleSci AI
nozero
昏睡的蟠桃
bc
zho
小杨同学
科研小民工
cdercder
从容芮
SYLH
HEIKU
史小菜
shinysparrow
压缩机
Agernon
Leon
DEF
22222
今天只做一件事
yanzu
爱静静
皖公网安备34019202002308
